Andersen-Tawil syndrome screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Andersen-Tawil syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{VKG}} | ||
==Overview== | ==Overview== | ||
Line 18: | Line 18: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category: Rare disease]] | ||
[[Category: Cardiology]] |
Revision as of 14:41, 3 February 2020
Andersen-Tawil syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Andersen-Tawil syndrome screening On the Web |
American Roentgen Ray Society Images of Andersen-Tawil syndrome screening |
Risk calculators and risk factors for Andersen-Tawil syndrome screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.
Screening
- There is insufficient evidence to recommend routine screening for Andersen-Tawil syndrome.
- But when a patient with positive KCNJ2 mutation and have no symptoms in Andersen-Tawil syndrome yearly screening with the following should be considered:
References
- ↑ Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K; et al. (1993). "GeneReviews®". PMID 20301441.
- ↑ Spillane, J; Kullmann, D M; Hanna, M G (2015). "Genetic neurological channelopathies: molecular genetics and clinical phenotypes". Journal of Neurology, Neurosurgery & Psychiatry: jnnp-2015–311233. doi:10.1136/jnnp-2015-311233. ISSN 0022-3050.